Royal Bank of Canada
SLDB icon

Royal Bank of Canada’s Solid Biosciences SLDB Stock Holding History

Royal Bank of Canada’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19K Sell
2,666
-1,630
-38% -$10.5K ﹤0.01% 5923
2025
Q4 		$24K Sell
4,296
-373,944
-99% -$2.03M ﹤0.01% 5948
2025
Q3 		$2.33M Sell
378,240
-5,415
-1% -$31.7K ﹤0.01% 3270
2025
Q2 		$1.87M Buy
383,655
+382,301
+28,235% +$1.35M ﹤0.01% 3361
2025
Q1 		$5K Buy
1,354
+1,288
+1,952% +$5.51K ﹤0.01% 6369
2024
Q4 		$0 Sell
66
-2,132
-97% -$11.7K ﹤0.01% 7219
2024
Q3 		$15K Sell
2,198
-10,777
-83% -$87.4K ﹤0.01% 6214
2024
Q2 		$73K Buy
12,975
+12,909
+19,559% +$116K ﹤0.01% 5456
2024
Q1 		$1K Sell
66
-2,994
-98% -$28K ﹤0.01% 6857
2023
Q4 		$18K Buy
3,060
+512
+20% +$1.64K ﹤0.01% 6350
2023
Q3 		$6K Buy
2,548
+1,413
+124% +$5.48K ﹤0.01% 6585
2023
Q2 		$6K Buy
1,135
+881
+347% +$4.96K ﹤0.01% 6632
2023
Q1 		$1K Sell
254
-70
-22% -$421 ﹤0.01% 6929
2022
Q4 		$2K Buy
324
+85
+36% +$557 ﹤0.01% 6944
2022
Q3 		$1K Buy
239
+54
+29% +$545 ﹤0.01% 7262
2022
Q2 		$2K Sell
185
-226
-55% -$2.35K ﹤0.01% 6994
2022
Q1 		$7K Sell
411
-476
-54% -$8.4K ﹤0.01% 7125
2021
Q4 		$23K Buy
887
+292
+49% +$8.92K ﹤0.01% 6743
2021
Q3 		$21K Sell
595
-177
-23% -$7.52K ﹤0.01% 6686
2021
Q2 		$42K Buy
772
+147
+24% +$9.71K ﹤0.01% 6153
2021
Q1 		$52K Sell
625
-154
-20% -$17K ﹤0.01% 5855
2020
Q4 		$89K Buy
779
+146
+23% +$9.23K ﹤0.01% 5400
2020
Q3 		$19K Sell
633
-2
-0.3% -$77 ﹤0.01% 5721
2020
Q2 		$28K Sell
635
-8
-1% -$332 ﹤0.01% 5457
2020
Q1 		$23K Buy
643
+48
+8% +$2.38K ﹤0.01% 5480
2019
Q4 		$39K Buy
595
+557
+1,466% +$61.5K ﹤0.01% 5557
2019
Q3 		$6K Buy
+38
New +$4.3K ﹤0.01% 5973
2018
Q4 		– Sell
-20
Closed -$14K – 7076
2018
Q3 		$14K Buy
20
+14
+233% +$8.8K ﹤0.01% 5856
2018
Q2 		$3K Buy
6
+2
+50% +$615 ﹤0.01% 6181
2018
Q1 		$0 Buy
+4
New +$1.35K ﹤0.01% 6745

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Royal Bank of Canada's SLDB Position: Q1 2026 in Review

Royal Bank of Canada reduced its Solid Biosciences (SLDB) stake by 38% in Q1 2026, selling an estimated $10.5K and leaving 2,666 shares worth $19K. The position accounts for ﹤0.01% of the portfolio, ranked #5923.

Royal Bank of Canada first reported a position in SLDB in Q1 2018 and has held it in 30 quarters since. The position peaked at $2.33M in Q3 2025. 150 funds tracked by Wall St. Rank hold SLDB as of Q1 2026.

  • Royal Bank of Canada held 2,666 shares of Solid Biosciences worth $19K as of Q1 2026.
  • Royal Bank of Canada sold 1,630 Solid Biosciences shares in Q1 2026, an estimated $10.5K.
  • Solid Biosciences made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5923 holding.
  • Royal Bank of Canada first reported a position in Solid Biosciences in Q1 2018 and has held it in 30 quarters since.
  • Royal Bank of Canada's Solid Biosciences position peaked at $2.33M in Q3 2025.
  • 150 funds tracked by Wall St. Rank held Solid Biosciences as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.